{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T10:53:39Z","timestamp":1753181619338,"version":"3.37.3"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Scientific Research Project of Heilongjiang Provincial Department of Health","award":["2013257"],"award-info":[{"award-number":["2013257"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>This study will systematically assess the efficacy and safety of Bacillus Calmette-Guerin (BCG) for patients with bladder cancer (BC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Literature searches will be performed in multiple electronic databases from inception to present: MEDLINE, EMBASE, CINAHL, Science Direct, Cochrane Library, Web of Science, and China National Knowledge Infrastructure. We will also examine grey literature through identifying conference proceedings, thesis, dissertations, and website of clinical trials registry. Two investigators will independently scan all citation titles, abstracts, and full-text studies. The study quality will be assessed by Cochrane Risk of Bias Tool. If possible, we will perform meta-analysis. Additional analyses will be carried out to test the potential sources of heterogeneity among included trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The present study will summarize high quality trials on investigating the efficacy and safety of BCG for patients with BC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The results of this study will supply helpful evidence to determine whether BCG is effective or not for BC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Study registration number:<\/jats:title>\n            <jats:p>INPLASY202070042.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000021930","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T17:04:00Z","timestamp":1598461440000},"page":"e21930","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of Bacillus Calmette-Guerin for bladder cancer"],"prefix":"10.1097","volume":"99","author":[{"given":"Zhi-hui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1319-7055","authenticated-orcid":false,"given":"Jing","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"5","DOI":"10.21037\/tau.2018.09.11","article-title":"Epidemiology, aetiology and screening of bladder cancer","volume":"8","author":"Cumberbatch","year":"2019","journal-title":"Transl Androl Urol"},{"key":"R2-20230915","first-page":"23","article-title":"Bladder Cancer Academy 2019 selected summaries","volume":"21","author":"Schulster","year":"2019","journal-title":"Rev Urol"},{"key":"R3-20230915","first-page":"15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s15006-018-1234-1","article-title":"Cancer of the urinary bladder: epidemiology, etiology, diagnosis of non-muscle invasive bladder cancer","volume":"160","author":"Karl","year":"2018","journal-title":"MMW Fortschr Med"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"17022","DOI":"10.1038\/nrdp.2017.22","article-title":"Bladder cancer","volume":"3","author":"Sanli","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"R9-20230915","first-page":"195","article-title":"Epidemiology and risk factors for the onset of urinary bladder cancer","volume":"60","author":"Radosavljevi\u0107","year":"2003","journal-title":"Vojnosanit Pregl"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jnci.2012.08.002","article-title":"Bladder cancer and schistosomiasis","volume":"24","author":"Zaghloul","year":"2012","journal-title":"J Egypt Natl Canc Inst"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s13340-018-0360-4","article-title":"Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies","volume":"10","author":"Meht\u00e4l\u00e4","year":"2018","journal-title":"Diabetol Int"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1136\/ard.2003.019125","article-title":"Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide","volume":"63","author":"Knight","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"40.e1","DOI":"10.1016\/j.urolonc.2019.09.013","article-title":"Impact of arsenic exposure on clinicopathological characteristics of bladder cancer: a comparative study between patients from an arsenic-exposed region and nonexposed reference sites","volume":"38","author":"Fern\u00e1ndez","year":"2020","journal-title":"Urol Oncol"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/1055-9965.EPI-14-0059","article-title":"Increased lung and bladder cancer incidence in adults after in utero and early-life arsenic exposure","volume":"23","author":"Steinmaus","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/MOU.0b013e32832eb4ef","article-title":"Environmental factors promoting bladder cancer","volume":"19","author":"Hirao","year":"2009","journal-title":"Curr Opin Urol"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ITT.S202006","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) therapy for bladder cancer: an update","volume":"9","author":"Guallar-Garrido","year":"2020","journal-title":"Immunotargets Ther"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/iju.14153","article-title":"Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: its definition and future therapeutic strategies","volume":"27","author":"Kikuchi","year":"2020","journal-title":"Int J Urol"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/apm.13011","article-title":"Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections","volume":"128","author":"Larsen","year":"2020","journal-title":"APMIS"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.juro.2015.08.075","article-title":"Randomized controlled study of the efficacy, safety and quality of life with low dose bacillus Calmette-Gu\u00e9rin instillation therapy for nonmuscle invasive bladder cancer","volume":"195","author":"Yokomizo","year":"2016","journal-title":"J Urol"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","article-title":"Bacillus Calmette-Gu\u00e9rin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study","volume":"57","author":"Duchek","year":"2010","journal-title":"Eur Urol"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000273461","article-title":"Bacillus Calmette-Gu\u00e9rin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study","volume":"84","author":"Porena","year":"2010","journal-title":"Urol Int"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","article-title":"The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel","year":"2006","journal-title":"J Urol"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1136\/bmj.320.7249.1574","article-title":"Empirical assessment of effect of publication bias on meta-analyses","volume":"320","author":"Sutton","year":"2000","journal-title":"BMJ"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:59:47Z","timestamp":1694825987000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021930"}},"subtitle":["A protocol of systematic review"],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":26,"journal-issue":{"issue":"35","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000021930","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,8,28]]}}}